Sigyn Therapeutics Inc SIGY
$0.03
Last Updated: Aug 19, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
SIGY Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Sigyn Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Sigyn Therapeutics Inc. Stock Analysis SIGY
United States N/A Nano Cap Sigyn Therapeutics, Inc. is a development-stage company, which focuses on creating therapeutic solutions that address unmet needs in global health. The company is headquartered in Beverly Hills, California and currently employs 4 full-time employees. The company went IPO on 2016-01-28. The firm's lead therapeutic candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Candidate treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines. Its development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. Its ImmunePrep platform enhances the performance of immunotherapeutic antibodies.
Sigyn Therapeutics Inc (SIGY) Chart
Financial Metrics & Statements of Sigyn Therapeutics Inc (SIGY)
FAQ's for Sigyn Therapeutics Inc (SIGY)
- As of August 2026, Sigyn Therapeutics Inc SIGY is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sigyn Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Sigyn Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Sigyn Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Sigyn Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Sigyn Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Sigyn Therapeutics Inc (SIGY)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
